Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3017
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines.

    To find out more about Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
4SC
Abbott
Abiogen
AC Immune
Adaptimmune
Adherex
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Ambit Biosciences
Amgen
Anavex Life Sciences
Antisense Pharma
Anza Therapeutics
Apotex
Apricus Biosciences
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
BioAlliance Pharma
Biocompatibles
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biolex
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
Borean Pharma
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Can-Fite BioPharma
Cancer Advances
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
Choongwae
Circadian Technologies
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
CuraGen
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dr Reddy’s
Dynavax Technologies
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Etubics
Exelixis
FasTrack Pharmaceuticals
Favrille
Forma Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
GenPat77
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Green Cross
Hayashibara
Heat Biologics
Heber Biotec
Heidelberg Pharma
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IGF Oncology
IkerChem
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
Incyte Corporation
Inex
Innate Pharma
InNexus Biotechnology
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Italfarmaco
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kiadis
Kinex
Kissei
Kyowa Hakko Kirin
Labopharm
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Meda
MediGene
MedImmune
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NicOx
NIH
Nippon Kayaku
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Noxxon
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
Otsuka
Oxford BioMedica
OXiGENE
PanaGin
Pepscan Therapeutics
Peptagen
Pfizer
Pharmaclon
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
POZEN
Pro-Pharmaceuticals
Progenics Pharmaceuticals
ProNAi Therapeutics
Protherics
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
responsif
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBIO
Scancell
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shionogi
Shire
Sigma-Tau
Simcere Pharmaceuticals
Spirogen
SRI International
SuperGen
SuppreMol
Supratek Pharma
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Targepeutics
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Viralytics
Virionics
ViroMed
Wyeth
XBiotech
Xencor
Xerion
Yakult Honsha
YM BioSciences
Zenotech
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
ADXS11-001
AE-37
aflibercept
AGS-003
alemtuzumab
amrubicin hydrochloride
Angiozyme
ANZ-207
astuprotimut-r
Auto TAG vaccine
AVX-701
belagenpumatucel-L
belinostat
bevacizumab
bexarotene
bortezomib
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
BV-NSCLC-001
capecitabine
catumaxomab
CB-10-01
CDX-1307
cediranib
cetuximab
CG-201
cladribine
CreaVax-PC
CV-9103
CV-9201
CVac
DCVax-prostate
denileukin diftitox
doxifluridine
E-75
elliptinium acetate
emepepimut-S
enzastaurin hydrochloride
epirubicin
everolimus
galiximab
GI-4000
GSK-2130579A
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
HS-110
ibritumomab tiuxetan
ICT-107
imMucin
IMO-2055
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interferon gamma
interleukin-12
irinotecan bead
irinotecan hydrochloride
ISA-P53-01
JX-594
MDX-1379
MGN-1601
MGN-1703
mitoxantrone
MVA-BN Her-2 vaccine
obinutuzumab
oblimersen sodium
ofatumumab
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
panitumumab
panobinostat
perifosine
pixantrone
poly-ICLC
polyclonal antibody stimulator
pralatrexate
PROSTVAC
PSMA ADC
raltitrexed
ramucirumab
razoxane
Reditux
regorafenib
Reximmune-C
rhIFN-alpha
rindopepimut
rintatolimod
rituximab
romidepsin
S-488410
SCIB-1
sipuleucel-T
sobuzoxane
Survivac
tegafur + uracil
tegafur + uracil + leucovorin
temsirolimus
teniposide
TG-4010
thymalfasin
tipapkinogene sovacivec
TroVax
TS-1
velimogene aliplasmid
verpasep caltespen
vitespen
VX-001
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines.
    To find out more about Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lymphoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Breast Cancer, Melanoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Melanoma and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More


Triple Analysis: Colorectal Cancer, Lymphoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Learn More